These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26830617)

  • 1. PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.
    Turkbey B; Lindenberg ML; Adler S; Kurdziel KA; McKinney YL; Weaver J; Vocke CD; Anver M; Bratslavsky G; Eclarinal P; Kwarteng G; Lin FI; Yaqub-Ogun N; Merino MJ; Linehan WM; Choyke PL; Metwalli AR
    Abdom Radiol (NY); 2016 Jan; 41(1):109-18. PubMed ID: 26830617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [(18) F]VM4-037 determined from PET/CT scans in healthy volunteers.
    Doss M; Kolb HC; Walsh JC; Mocharla VP; Zhu Z; Haka M; Alpaugh RK; Chen DY; Yu JQ
    Mol Imaging Biol; 2014 Oct; 16(5):739-46. PubMed ID: 24696183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma.
    Zhu W; Li X; Zheng G; Bai C; Ji Z; Zhang H; Xing H; Zhang Y; Huo L
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3116-3125. PubMed ID: 37246998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation.
    Zhu H; Zhao S; Zuo C; Ren F
    AJR Am J Roentgenol; 2020 Sep; 215(3):645-651. PubMed ID: 32755159
    [No Abstract]   [Full Text] [Related]  

  • 5. Positron Emission Tomography/Computed Tomography with
    Hekman MCH; Rijpkema M; Aarntzen EH; Mulder SF; Langenhuijsen JF; Oosterwijk E; Boerman OC; Oyen WJG; Mulders PFA
    Eur Urol; 2018 Sep; 74(3):257-260. PubMed ID: 29730017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
    Gerety EL; Lawrence EM; Wason J; Yan H; Hilborne S; Buscombe J; Cheow HK; Shaw AS; Bird N; Fife K; Heard S; Lomas DJ; Matakidou A; Soloviev D; Eisen T; Gallagher FA
    Ann Oncol; 2015 Oct; 26(10):2113-8. PubMed ID: 26202597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [(18)F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models.
    Peeters SG; Dubois L; Lieuwes NG; Laan D; Mooijer M; Schuit RC; Vullo D; Supuran CT; Eriksson J; Windhorst AD; Lambin P
    Mol Imaging Biol; 2015 Oct; 17(5):615-9. PubMed ID: 25708744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.
    Muselaers CH; Boerman OC; Oosterwijk E; Langenhuijsen JF; Oyen WJ; Mulders PF
    Eur Urol; 2013 Jun; 63(6):1101-6. PubMed ID: 23453421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
    Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
    Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
    Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
    BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice.
    Stillebroer AB; Franssen GM; Mulders PF; Oyen WJ; van Dongen GA; Laverman P; Oosterwijk E; Boerman OC
    Cancer Biother Radiopharm; 2013 Sep; 28(7):510-5. PubMed ID: 23697926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study.
    Hekman MC; Rijpkema M; Muselaers CH; Oosterwijk E; Hulsbergen-Van de Kaa CA; Boerman OC; Oyen WJ; Langenhuijsen JF; Mulders PF
    Theranostics; 2018; 8(8):2161-2170. PubMed ID: 29721070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Microdosing Study with
    Kulterer OC; Pfaff S; Wadsak W; Garstka N; Remzi M; Vraka C; Nics L; Mitterhauser M; Bootz F; Cazzamalli S; Krall N; Neri D; Haug AR
    J Nucl Med; 2021 Mar; 62(3):360-365. PubMed ID: 32680925
    [No Abstract]   [Full Text] [Related]  

  • 16. Head-to-head comparison of [
    Wang G; Li L; Wang J; Zang J; Chen J; Xiao Y; Fan X; Zhu L; Kung HF; Zhu Z
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1499-1509. PubMed ID: 36600099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT with (124)I-cG250: great potential and some open questions.
    Khandani AH; Rathmell WK; Wallen EM; Ivanovic M
    AJR Am J Roentgenol; 2014 Aug; 203(2):261-2. PubMed ID: 25055257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Malignant tumor with false negative 18F-FDG PET image].
    Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
    Khandani AH; Cowey CL; Moore DT; Gohil H; Rathmell WK
    Nucl Med Commun; 2012 Sep; 33(9):967-73. PubMed ID: 22714005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
    Minn I; Koo SM; Lee HS; Brummet M; Rowe SP; Gorin MA; Sysa-Shah P; Lewis WD; Ahn HH; Wang Y; Banerjee SR; Mease RC; Nimmagadda S; Allaf ME; Pomper MG; Yang X
    Oncotarget; 2016 Aug; 7(35):56471-56479. PubMed ID: 27437764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.